| Product Code: ETC8854049 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Closely related to the general vasomotor symptoms market, the VMS treatment market focuses on menopausal patients. The use of hormonal therapy, SSRIs, and herbal remedies like black cohosh and soy isoflavones is becoming more common. Increased educational campaigns and womens wellness programs are helping reduce stigma around menopause and supporting market development.
A sub-segment of the broader menopausal treatment space, the VMS treatment market is growing as women seek relief from quality-of-life-disrupting symptoms. While HRT dominates prescriptions, theres a growing shift toward plant-based and bioidentical hormone treatments. Educational initiatives by OB-GYNs and wellness clinics are playing a role in encouraging early intervention, especially among urban and middle-income populations.
Beyond cultural barriers, the VMS treatment market faces gaps in patient education and a lack of trained gynecologists outside urban areas. Accessibility to hormone and non-hormone therapies is still limited by supply constraints and high treatment costs.
This subset of the menopausal treatment segment offers further potential, particularly in non-hormonal pharmaceuticals and herbal therapies. Brands offering natural or prescription VMS treatments could capture market share by collaborating with OB-GYN networks, leveraging digital marketing, and supplying wellness clinics focused on midlife women.
The DOH promotes awareness and health interventions for menopausal women, although VMS-specific programs are minimal. Treatments like hormone replacement therapies are FDA-regulated and available via prescription. Government clinics offer limited options through womens health services.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Industry Life Cycle |
3.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Porter's Five Forces |
3.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness among women about the importance of managing vasomotor menopausal symptoms (VMS) |
4.2.2 Growing aging population in the Philippines |
4.2.3 Technological advancements leading to the development of more effective VMS treatment options |
4.3 Market Restraints |
4.3.1 Limited access to healthcare facilities and specialists in certain regions of the Philippines |
4.3.2 Cultural stigmas associated with menopause leading to underreporting of symptoms |
4.3.3 Affordability issues for certain segments of the population in accessing VMS treatment |
5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends |
6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Types |
6.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Antidepressants, 2021- 2031F |
6.1.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Fluoxetine, 2021- 2031F |
6.1.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Paroxetine, 2021- 2031F |
6.1.6 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Sertraline, 2021- 2031F |
6.1.7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.1.8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Anticonvulsant, 2021- 2031F |
6.1.9 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.1.10 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Phenobarbital, 2021- 2031F |
6.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.5 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Import-Export Trade Statistics |
7.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Export to Major Countries |
7.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Imports from Major Countries |
8 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Key Performance Indicators |
8.1 Average age of women seeking VMS treatment in the Philippines |
8.2 Number of healthcare facilities offering specialized VMS treatment services |
8.3 Percentage of women receiving regular VMS treatment consultations |
8.4 Adoption rate of new technological advancements in VMS treatment |
8.5 Patient satisfaction scores related to VMS treatment services |
9 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Opportunity Assessment |
9.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market - Competitive Landscape |
10.1 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Revenue Share, By Companies, 2024 |
10.2 Philippines Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here